Safety & Efficacy of ICL670 vs. Deferoxamine in Beta-thalassemia Patients With Iron Overload Due to Blood Transfusions
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to deterimine if the new orally active iron chelator, ICL670, is
as effective and as safe as deferoxamine in preventing accumulation of iron in the body while
a patient is undergoing repeated blood transfusions.